Ex-MiMedx Employee Jake Heikkinen Files Counterclaims Alleging Schemes 'To Bilk Medicare' and 'Incentivize and Pressure Healthcare Providers' per Mintz Attorneys MARIETTA, Ga., Sept. 4, 2024 /PRNewswire/ -- The third of 10 defendants who were sued earlier this year by MiMedx Group, Inc. (NASDAQ: MDXG) today filed counterclaims against the company. Jake Heikkinen, a former MiMedx employee, states in the filing that he left the placental biologics company because of "MiMedx's schemes to bilk Medicare and othe ...

Product Launch - MiMedx Group Inc announced the commercial launch of HELIOGEN™ Fibrillar Collagen Matrix, a particulate xenograft product designed for complex wound management in surgical settings [1] - HELIOGEN contains Type I and Type III collagen, mimicking the native composition of structural connective tissue, and is shelf-stable [1] Strategic Expansion - The launch of HELIOGEN represents a strategic initiative to expand the company's surgical footprint, following the successful introduction of two new surgical products in late 2022 [2] - HELIOGEN is the company's first xenograft option and 510(k) cleared product, complementing its existing placental-based solutions in the surgical market [2] Product Features - HELIOGEN is a bovine-derived collagen matrix product indicated for managing moderately to heavily exudating wounds and controlling minor bleeding [3] - The product supports wound healing by allowing cell adhesion and migration into the wound site, and is provided in particulate form to conform to various wound types [3] Company Overview - MiMedx is a pioneer in wound care, with over a decade of experience in helping clinicians manage chronic and hard-to-heal wounds [4] - The company focuses on providing a leading portfolio of products for wound care, burn, and surgical sectors, aiming to be the global leader in healing solutions through innovation [4]

Marks MIMEDX's first publication in the 5th most-cited journal in the world About MIMEDX Study adds to the Company's growing body of evidence and expands the understanding of the regulatory capabilities of its DHACM and LHACM allografts on the fibrotic process The study evaluated two configurations of PURION processed placental-based allografts for their ability to regulate fibrotic processes as modeled in a physiologically relevant in vitro system. Both dehydrated human amnion chorion membrane (DHACM) and ...

MARIETTA, Ga., July 22, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced the publication of a peer reviewed study characterizing a potential mechanism by which placental-based allografts modulate the occurrence of scarring and fibrosis in surgical procedures. The article, "Human amniotic membrane modulates collagen production and deposition in vitro" represents the Company's first publication in Nature and can be accessed online here. About MIMEDX Marks ...

Rigorous Clinical Trials: The ongoing Phase 3 trials are being run according to FDA and industry standards that ensure the integrity of all reported results. Mr. Barry succeeds Remi Barbier, the Company's Chairman, President and CEO, who resigned from the Company and the Board. Mr. Barbier will remain employed by the Company until September 13, 2024 in a nonexecutive capacity, without duties or responsibilities. Mr. Barry said that in addition to the leadership changes, the Board has added Pierre Gravier as ...

Mr. Capper continued, "With today's announcement, Kim is expanding her area of responsibility to include marketing and international commercial operations, where we will continue to benefit from her guidance. I look forward to working alongside of Kim and the rest of the MIMEDX team as we continue the process of building MIMEDX into a world class MedTech company." MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-hea ...

Net Sales of $85 Million Grew 18% Year-Over-Year for the First Quarter First Quarter GAAP Net Income was $9 Million First Quarter Adjusted EBITDA of $19 Million, or 22% of Net Sales Management to Host Conference Call Today, April 30, 2024, at 4:30 PM ET Exhibit 99.1 MIMEDX Announces First Quarter 2024 Operating and Financial Results MARIETTA, Ga., April 30, 2024 — MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the first quarter 2024. Recent ...

For the Quarterly Period Ended March 31, 2024 OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Florida 26-2792552 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 1775 West Oak Commons Ct NE Marietta, GA 30062 (Address of principal executive offices) (Zip Code) (770) 651-9100 (Registrant's telephone number, including area code) ☐ TRA ...

MARIETTA, Ga., March 20, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it has entered into an agreement with TELA Bio, Inc. to obtain exclusive rights to its manufacturing and supply agreement with Regenity Biosciences that will enable the Company to add xenograft products to its portfolio of Advanced Wound Care and Surgical solutions. Commenting on this agreement, Joseph H. Capper, MIMEDX Chief Executive Officer, stated, "We are excited to announ ...

MARIETTA, Ga., March 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointments of Tiffany Olson and Dorothy Puhy to its Board of Directors, effective as of March 1, 2024. Ms. Olson and Ms. Puhy each bring extensive and relevant experience across the healthcare industry, with demonstrated records of executive leadership, strategic counsel and shareholder value creation. In connection with these appointments, the Board of Directors unanimously a ...